Neurizon Therapeutics Limited has released a press release.
Positive Interim Study Results from OLE Study in ALS
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Completes Share Purchase Plan
- Monepantel Selected for Entry into HEALEY ALS Platform Trial
- Share Purchase Plan Offer Booklet
- PharmAust raises $10 million via Placement and announces SPP
- OLE Study update reveals impressive Survival Data
Later from Neurizon Therapeutics
- Appendix 4E and 2024 Annual Report
- PharmAust Receives R&D Tax Incentive Rebate
- Positive opinion received on OMPD for NUZ-001 in Europe
- NUZ-001 Reduces Aggregation of Key ALS Disease Target
- Neurizon Presents Positive Preclinical Data on NUZ-001
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics